Authors

Latest:

Dr. Lee Highlights Key Takeaways From SPARTAN Trial in M0CRPC

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, highlights key takeaways from the phase III SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Richard Joseph, MD

Latest:

Dr. Joseph on Necessary Improvements on Immunotherapy in Melanoma

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Richard Kim, MD

Latest:

Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC

Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.

Richard Kim, MD, Moffitt Cancer Center

Latest:

Updates in Frontline Treatment of Metastatic Liver Cancer

Richard Kim, MD, University of South Florida College of Medicine

Richard Kinh Gian Do, MD, PhD

Latest:

Dr. Do on the Assessment of Tumor Response in Liver Cancer

Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in liver cancer.

Richard L. Schilsky, MD

Latest:

Dr. Schilsky on the Impact of Sequestration on the FDA

Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses sequestration and the effect on the FDA.

Richard L. Shapiro, MD

Latest:

Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma

Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.

Richard M. Goldberg, MD, Ohio State University Comprehensive Cancer Center

Richard M. Harris, MD, Cedars Sinai

Richard M. Harris, MD, UroPartners, LLC

Richard M. Levine, MD

Latest:

Dr. Levine on Evolving Treatment Options for Patients With mCRPC

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Richard M. Stone, MD

Latest:

Dr. Stone on the Use of E-selectin as a Target to Overcome Treatment Resistance in AML

Richard M. Stone, MD, discusses potential ways to address drug resistance in acute myeloid leukemia by targeting E-selectin.

Richard M. Stone, MD, Dana-Farber Cancer Institute

Latest:

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Richard Moscicki, MD

Latest:

Dr. Moscicki on His Experience With Lysosomal Diseases

Dr. Richard Moscicki from Chief Medical Officer, Genzyme Corporation, on His Experience With Lysosomal Diseases

Richard P. McQuellon, PhD, HSP-P

Latest:

Weaving Compassion Into the Fabric of Cancer Treatment

The Comprehensive Cancer Center at Wake Forest Baptist Medical Center provides programs and services that are integrated into the ongoing care of patients in order to make professional assistance available easily and seamlessly.

Richard Pazdur, MD

Latest:

Dr. Pazdur on Breakthrough Designation Requirements

Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Richard R. Furman, MD

Latest:

Dr. Furman on Current Treatment Options in CLL

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Richard R. Furman, MD, NewYork-Presbyterian Medical Center

Richard R. Furman, MD, Weill Cornell Medical College